Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis.

Ritchey L, Ha T, Otsuka A, Kabashima K, Wang D, Wang Y, Lowy DR, Tosato G.

Oncogene. 2019 Aug 13. doi: 10.1038/s41388-019-0944-x. [Epub ahead of print]

PMID:
31409902
2.

SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions.

Tripathi BK, Anderman MF, Qian X, Zhou M, Wang D, Papageorge AG, Lowy DR.

J Cell Biol. 2019 Jul 15. pii: jcb.201810098. doi: 10.1083/jcb.201810098. [Epub ahead of print]

PMID:
31308216
3.

Human Papillomavirus 16 Capsids Mediate Nuclear Entry during Infection.

Day PM, Weisberg AS, Thompson CD, Hughes MM, Pang YY, Lowy DR, Schiller JT.

J Virol. 2019 Jul 17;93(15). pii: e00454-19. doi: 10.1128/JVI.00454-19. Print 2019 Aug 1.

PMID:
31092566
4.

A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells.

Çuburu N, Kim R, Guittard GC, Thompson CD, Day PM, Hamm DE, Pang YS, Graham BS, Lowy DR, Schiller JT.

J Immunol. 2019 Feb 15;202(4):1250-1264. doi: 10.4049/jimmunol.1800219. Epub 2019 Jan 11.

PMID:
30635393
5.

The Partnership for Accelerating Cancer Therapies.

Baker RG, Hoos AX, Adam SJ, Wholley D, Doroshow JH, Lowy DR, Tabak LA, Collins FS.

Cancer J. 2018 May/Jun;24(3):111-114. doi: 10.1097/PPO.0000000000000321. Review.

6.

Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment.

Ashraf S, Kudo H, Rao J, Kikuchi A, Widmeier E, Lawson JA, Tan W, Hermle T, Warejko JK, Shril S, Airik M, Jobst-Schwan T, Lovric S, Braun DA, Gee HY, Schapiro D, Majmundar AJ, Sadowski CE, Pabst WL, Daga A, van der Ven AT, Schmidt JM, Low BC, Gupta AB, Tripathi BK, Wong J, Campbell K, Metcalfe K, Schanze D, Niihori T, Kaito H, Nozu K, Tsukaguchi H, Tanaka R, Hamahira K, Kobayashi Y, Takizawa T, Funayama R, Nakayama K, Aoki Y, Kumagai N, Iijima K, Fehrenbach H, Kari JA, El Desoky S, Jalalah S, Bogdanovic R, Stajić N, Zappel H, Rakhmetova A, Wassmer SR, Jungraithmayr T, Strehlau J, Kumar AS, Bagga A, Soliman NA, Mane SM, Kaufman L, Lowy DR, Jairajpuri MA, Lifton RP, Pei Y, Zenker M, Kure S, Hildebrandt F.

Nat Commun. 2018 May 17;9(1):1960. doi: 10.1038/s41467-018-04193-w.

7.

Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies.

Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, Schiffman M, Rodriguez AC, Chanock S, Jimenez S, Schussler J, Gail MH, Safaeian M, Kemp TJ, Cortes B, Pinto LA, Hildesheim A, Gonzalez P; Costa Rica HPV Vaccine Trial (CVT) Group.

Vaccine. 2018 Aug 6;36(32 Pt A):4774-4782. doi: 10.1016/j.vaccine.2017.12.078. Epub 2018 Feb 1.

8.

Implementing the Cancer Moonshot and beyond.

Lowy DR, Singer DS.

Lancet Oncol. 2017 Nov;18(11):e622-e623. doi: 10.1016/S1470-2045(17)30797-0. Epub 2017 Oct 31. No abstract available.

9.

Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.

Sánchez-Martín D, Otsuka A, Kabashima K, Ha T, Wang D, Qian X, Lowy DR, Tosato G.

J Natl Cancer Inst. 2018 Apr 1;110(4):390-399. doi: 10.1093/jnci/djx219.

10.

Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.

Çuburu N, Khan S, Thompson CD, Kim R, Vellinga J, Zahn R, Lowy DR, Scheper G, Schiller JT.

Int J Cancer. 2018 Apr 1;142(7):1467-1479. doi: 10.1002/ijc.31166. Epub 2017 Dec 1.

11.

Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.

Tripathi BK, Grant T, Qian X, Zhou M, Mertins P, Wang D, Papageorge AG, Tarasov SG, Hunter KW, Carr SA, Lowy DR.

J Cell Biol. 2017 Dec 4;216(12):4255-4270. doi: 10.1083/jcb.201703105. Epub 2017 Nov 7.

12.

Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.

Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, van Doorn LJ, Schussler J, Lowy DR, Schiller J, Schiffman MT, Rodriguez AC, Gail MH, Hildesheim A, Gonzalez P, Pinto LA, Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx158.

13.

Preventing Cancer and Other Diseases Caused by Human Papillomavirus Infection: 2017 Lasker-DeBakey Clinical Research Award.

Lowy DR, Schiller JT.

JAMA. 2017 Sep 12;318(10):901-902. doi: 10.1001/jama.2017.11706. No abstract available.

14.

Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions.

Cerqueira C, Thompson CD, Day PM, Pang YS, Lowy DR, Schiller JT.

Mol Ther Methods Clin Dev. 2017 Apr 19;5:165-179. doi: 10.1016/j.omtm.2017.04.005. eCollection 2017 Jun 16.

15.

DLC1: a tumor suppressor that regulates Rho signaling.

Tripathi BK, Lowy DR.

Oncotarget. 2017 Apr 25;8(17):27674-27675. doi: 10.18632/oncotarget.16805. No abstract available.

16.

Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism.

Day PM, Thompson CD, Lowy DR, Schiller JT.

J Virol. 2017 Apr 28;91(10). pii: e00168-17. doi: 10.1128/JVI.00168-17. Print 2017 May 15.

17.

Toward a Shared Vision for Cancer Genomic Data.

Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, Staudt LM.

N Engl J Med. 2016 Sep 22;375(12):1109-12. doi: 10.1056/NEJMp1607591. No abstract available.

18.

Involvement of Nucleophosmin (NPM1/B23) in Assembly of Infectious HPV16 Capsids.

Day PM, Thompson CD, Pang YY, Lowy DR, Schiller JT.

Papillomavirus Res. 2015 Dec;1:74-89. Epub 2015 Jun 25.

19.

LD Motif Recognition by Talin: Structure of the Talin-DLC1 Complex.

Zacharchenko T, Qian X, Goult BT, Jethwa D, Almeida TB, Ballestrem C, Critchley DR, Lowy DR, Barsukov IL.

Structure. 2016 Jul 6;24(7):1130-41. doi: 10.1016/j.str.2016.04.016. Epub 2016 Jun 2.

20.

DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers.

Wang D, Qian X, Rajaram M, Durkin ME, Lowy DR.

Oncotarget. 2016 Jul 19;7(29):45144-45157. doi: 10.18632/oncotarget.9266.

21.

Aiming High--Changing the Trajectory for Cancer.

Lowy DR, Collins FS.

N Engl J Med. 2016 May 19;374(20):1901-4. doi: 10.1056/NEJMp1600894. Epub 2016 Apr 4. No abstract available.

22.

Basic science: Bedrock of progress.

Collins FS, Anderson JM, Austin CP, Battey JF, Birnbaum LS, Briggs JP, Clayton JA, Cuthbert B, Eisinger RW, Fauci AS, Gallin JI, Gibbons GH, Glass RI, Gottesman MM, Gray PA, Green ED, Greider FB, Hodes R, Hudson KL, Humphreys B, Katz SI, Koob GF, Koroshetz WJ, Lauer MS, Lorsch JR, Lowy DR, McGowan JJ, Murray DM, Nakamura R, Norris A, Perez-Stable EJ, Pettigrew RI, Riley WT, Rodgers GP, Sieving PA, Somerman MJ, Spong CY, Tabak LA, Volkow ND, Wilder EL.

Science. 2016 Mar 25;351(6280):1405. doi: 10.1126/science.351.6280.1405-a. No abstract available.

23.

Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.

Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, Porras C, Schiffman M, Sidawy M, Schiller JT, Lowy DR, Herrero R; Costa Rica HPV Vaccine Trial (CVT) Group.

Am J Obstet Gynecol. 2016 Aug;215(2):212.e1-212.e15. doi: 10.1016/j.ajog.2016.02.021. Epub 2016 Feb 16.

24.
25.

A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging.

Cerqueira C, Pang YY, Day PM, Thompson CD, Buck CB, Lowy DR, Schiller JT.

J Virol. 2015 Nov 11;90(2):1096-107. doi: 10.1128/JVI.02497-15. Print 2016 Jan 15.

26.

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, Lowy DR, Porras C, Schiller JT, Quint W, Jimenez S, Safaeian M, Struijk L, Schussler J, Hildesheim A, Gonzalez P; Costa Rica HPV Vaccine Trial (CVT) Group.

J Natl Cancer Inst. 2015 Oct 14;108(1). pii: djv302. doi: 10.1093/jnci/djv302. Print 2016 Jan.

27.

Human papillomavirus capsids preferentially bind and infect tumor cells.

Kines RC, Cerio RJ, Roberts JN, Thompson CD, de Los Pinos E, Lowy DR, Schiller JT.

Int J Cancer. 2016 Feb 15;138(4):901-11. doi: 10.1002/ijc.29823. Epub 2015 Oct 27.

28.

Reply to Nalin.

Schiller JT, Lowy DR.

J Infect Dis. 2015 Dec 15;212(12):2021-2. doi: 10.1093/infdis/jiv394. Epub 2015 Aug 12. No abstract available.

29.

Correction to Lancet Oncol 2015; 16: e227. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging.

Lowy DR, Herrero R, Hildesheim A.

Lancet Oncol. 2015 Jul;16(7):e313. doi: 10.1016/S1470-2045(15)00072-8. No abstract available.

PMID:
26149883
30.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group.

Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.

31.

Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging.

Lowy DR, Herrero R, Hildesheim A; Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials.

Lancet Oncol. 2015 May;16(5):e226-33. doi: 10.1016/S1470-2045(15)70075-6. Review. Erratum in: Lancet Oncol. 2015 Jul;16(7):e313.

PMID:
25943067
32.

The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane.

Day PM, Thompson CD, Lowy DR, Schiller JT.

Virology. 2015 Jul;481:79-94. doi: 10.1016/j.virol.2015.02.021. Epub 2015 Mar 12.

33.

Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.

Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, Wacholder S, Gonzalez P, Schiller JT, Lowy DR, Esser M, Matys K, Poncelet S, Herrero R, Hildesheim A, Pinto LA, Safaeian M.

Hum Vaccin Immunother. 2014;10(10):2965-74. doi: 10.4161/21645515.2014.972811.

34.

CDK5 is a major regulator of the tumor suppressor DLC1.

Tripathi BK, Qian X, Mertins P, Wang D, Papageorge AG, Carr SA, Lowy DR.

J Cell Biol. 2014 Dec 8;207(5):627-42. doi: 10.1083/jcb.201405105. Epub 2014 Dec 1.

35.

Raising expectations for subunit vaccine.

Schiller JT, Lowy DR.

J Infect Dis. 2015 May 1;211(9):1373-5. doi: 10.1093/infdis/jiu648. Epub 2014 Nov 24. Review.

36.

Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.

Gordon SN, Doster MN, Kines RC, Keele BF, Brocca-Cofano E, Guan Y, Pegu P, Liyanage NP, Vaccari M, Cuburu N, Buck CB, Ferrari G, Montefiori D, Piatak M Jr, Lifson JD, Xenophontos AM, Venzon D, Robert-Guroff M, Graham BS, Lowy DR, Schiller JT, Franchini G.

J Immunol. 2014 Dec 15;193(12):6172-83. doi: 10.4049/jimmunol.1401504. Epub 2014 Nov 14.

37.
38.

Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.

Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M; Costa Rica Vaccine Trial Group.

Am J Epidemiol. 2014 Sep 15;180(6):599-607. doi: 10.1093/aje/kwu168. Epub 2014 Aug 19.

39.

The Cdk5 activator P39 specifically links muskelin to myosin II and regulates stress fiber formation and actin organization in lens.

Tripathi BK, Lowy DR, Zelenka PS.

Exp Cell Res. 2015 Jan 1;330(1):186-98. doi: 10.1016/j.yexcr.2014.08.003. Epub 2014 Aug 13.

40.

Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1.

Handisurya A, Day PM, Thompson CD, Bonelli M, Lowy DR, Schiller JT.

PLoS Pathog. 2014 Aug 14;10(8):e1004314. doi: 10.1371/journal.ppat.1004314. eCollection 2014 Aug.

41.

Maturation of the human papillomavirus 16 capsid.

Cardone G, Moyer AL, Cheng N, Thompson CD, Dvoretzky I, Lowy DR, Schiller JT, Steven AC, Buck CB, Trus BL.

MBio. 2014 Aug 5;5(4):e01104-14. doi: 10.1128/mBio.01104-14.

42.

Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.

Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2014 Dec 15;210(12):1890-9. doi: 10.1093/infdis/jiu357. Epub 2014 Jun 23.

43.

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group.

Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203. Erratum in: Cancer Prev Res (Phila). 2016 Jan;9(1):116-7.

44.

Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization.

Handisurya A, Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT.

J Virol. 2013 Dec;87(24):13214-25. doi: 10.1128/JVI.02162-13. Epub 2013 Sep 25.

45.

Isolation of Mouse Embryo Fibroblasts.

Durkin ME, Qian X, Popescu NC, Lowy DR.

Bio Protoc. 2013 Sep 20;3(18). pii: e908.

46.

Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.

Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, Rodriguez AC, Schiffman M, Quint W, Lowy DR, Porras C, Delvecchio C, Katki HA, Jimenez S, Safaeian M, Schiller J, Solomon D, Wacholder S, Herrero R, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2013 Nov 15;208(10):1643-52. doi: 10.1093/infdis/jit369. Epub 2013 Sep 6.

47.

Virus infection and human cancer: an overview.

Schiller JT, Lowy DR.

Recent Results Cancer Res. 2014;193:1-10. doi: 10.1007/978-3-642-38965-8_1.

PMID:
24008290
48.

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.

Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR; CVT Vaccine Group.

PLoS One. 2013 Jul 17;8(7):e68329. doi: 10.1371/journal.pone.0068329. Print 2013.

49.
50.

In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells.

Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F.

BMC Cancer. 2013 Apr 22;13:198. doi: 10.1186/1471-2407-13-198.

Supplemental Content

Support Center